Henry Schein, Inc. (HSIC) is expected to release first-quarter 2024 results on May 7 before the opening bell.The company posted adjusted earnings per share (EPS) of 66 cents in the last reported quarter, which missed the Zacks Consensus Estimate by 5.71%. In the trailing four quarters, Henry Schein’s earnings matched estimates once, surpassed once and missed in two quarters. The average negative surprise is 0.83%.Let’s see how things have shaped up prior to this announcement.Factors at PlayHealth Care Distr ...

Henry Schein (HSIC) is well-positioned to gain from its extensive global foothold and diverse channel mix. However, unfavorable currency movement and global economic uncertainties continue to affect the business. The stock carries a Zacks Rank #3 (Hold) currently.Henry Schein’s business boasts a broad global footprint with 61 distribution centers. Apart from North America, the company has a presence in Australia and New Zealand as well as in emerging nations like China, Brazil, Israel, the Czech Republic an ...

Henry Schein, Inc. (HSIC) is poised to experience growth in the coming quarters, backed by its encouraging strategy to expand digital dentistry globally. Niche acquisitions and partnerships have consistently fueled the company's revenue growth. Further, Henry Schein is upbeat about its dental technology joint venture (JV), Henry Schein One, which has been progressing well despite a challenging business environment.Meanwhile, the impact of the cybersecurity incident on HSIC’s operations remains concerning. M ...

Henry Schein, Inc. (HSIC) has recently completed the acquisition of orthopedic player TriMed for an undisclosed financial term. Integration of TriMed’s business will help the company to provide a wider range of surgical solutions to the existing Integrated Delivery Networks and Ambulatory Surgery Center customers. This will strengthen HSIC’s long-standing relationship with them.Headquartered in Santa Clarita, CA, TriMed is a global developer of solutions for the orthopedic treatment of lower extremities (fo ...

Henry Schein to Maximize Viome's Reach Among Dental and Medical Practices With Patient-Centric and Preventive Models of Care BELLEVUE, Wash., April 2, 2024 /PRNewswire/ -- Viome, a leading innovator of health technology and personalized health solutions, is partnering with Henry Schein to provide better access to Viome's Oral Health Pro™ With CancerDetect™.* Viome's laboratory-developed test* helps detect early biomarkers of oral and throat cancers, enhancing practitioners' ability to effectively harness th ...

Henry Schein has been recognized since 2012 and is one of only two honorees in the Healthcare Products industry. (Graphic: Business Wire)Henry Schein has been recognized since 2012 and is one of only two honorees in the Healthcare Products industry. (Graphic: Business Wire)MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, has received the 2024 World’s Most Ethical Companies® recognition ...

Financial Performance & Impact Factors - Worldwide sales decreased by 10.5% in Q4 2023, with total sales of $3.017 billion compared to $3.371 billion in Q4 2022 [10, 11, 14, 35, 51] - The cybersecurity incident led to an estimated reduction in sales of $350 million to $400 million, representing approximately 10% to 12% impact [10, 11, 15] - Non-GAAP diluted EPS was $0.66 in Q4 2023, a decrease of 51.1% compared to $1.35 in Q4 2022 [10, 11, 33, 51] - The cybersecurity incident impacted EPS by approximately $0.70-$0.75 per diluted share, and acquisition-related expenses & adjustments added $0.05 [10, 24] - Operating income decreased by 46.7% from $72 million to $39 million [11, 61] Segment Performance - Global Dental sales experienced a decrease of 10.2% [10, 14, 69] - Global Medical sales decreased by 14.9% [10, 14, 55] - Global Technology/VAS sales increased by 13.4% [10, 14, 29, 38, 41] - Dental Specialties sales grew by 17.2% [10, 41] Strategic Initiatives & Outlook - The company introduced 2024 Non-GAAP Diluted EPS guidance of $5.00 to $5.16, reflecting growth of 11% to 15% compared with 2023 [9, 45] - Adjusted EBITDA is expected to increase by more than 15% vs 2023 [9, 45]

Financial Data and Key Metrics Changes - The fourth quarter global sales were $3.0 billion, reflecting an LCI sales decrease of 12%, primarily impacted by the cybersecurity incident, which affected sales growth by an estimated 10% to 12% [25][57] - The non-GAAP operating margin for the fourth quarter was 4.86%, a decline of 279 basis points compared to the prior year, largely due to the cybersecurity incident and sales recovery initiatives [26][59] - Fourth quarter 2023 non-GAAP EPS was $0.66, down from $1.35 in the prior year, with the cybersecurity incident impacting EPS by approximately $0.70 to $0.75 [59][60] Business Line Data and Key Metrics Changes - Global Dental sales were $1.8 billion, with LCI sales decreasing by 10.9%, affected by the cybersecurity incident [28] - Global Technology and Value-Added Services sales were $212 million, with total sales growth of 13.4% and LCI sales growth of 7.1% [29] - Global Medical sales were $1.0 billion, with LCI sales decreasing by 17% due to the cybersecurity incident [30] Market Data and Key Metrics Changes - North American and international distribution businesses experienced merchandise sales below pre-cybersecurity levels, with a low-single digit percentage headwind to merchandise sales growth [12] - European, Latin American, and Asian markets posted significant growth, mainly from acquisitions, while U.S. implant sales showed low-single digit growth [16] - The late flu season negatively impacted patient visits and point of care diagnostic sales, but is expected to drive higher sales in the first quarter [52][47] Company Strategy and Development Direction - The company is focused on executing its BOLD+1 Strategic Plan, aiming for high-single digit to low-double digit operating income and EPS growth [13][54] - The company plans to enhance technology and product development, particularly in integrated digital workflows and specialty products [55] - Recent acquisitions, including a majority interest in TriMed, are expected to complement existing product lines and drive growth [19][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery from the cybersecurity incident and expects to strengthen market position despite short-term impacts [5][69] - The company anticipates that sales of COVID test kits and PPE have normalized, with some residual impact from lower PPE pricing expected in the first quarter [35][92] - Management expects 2024 non-GAAP diluted EPS to be in the range of $5 to $5.16, reflecting growth of 11% to 15% compared to 2023 [34][92] Other Important Information - The company repurchased approximately 692,000 shares in the fourth quarter at an average price of $72.32 per share, totaling $50 million [30] - Operating cash flow for the fourth quarter was an outflow of $32 million, compared to positive $254 million in the previous year, primarily due to delayed billings related to the cybersecurity incident [64] - The company expects to incur additional expenses related to the cybersecurity incident in 2024, but at a lower amount [65] Q&A Session Summary Question: Can you provide more detail on the end market environment and quantify the expected push out into Q1 from the cybersecurity impact, specifically on equipment? - Management indicated that dental equipment backlog was generally flat, with North America down mid-single digits and international backlog high-single digits. They expect good equipment sales growth in Q1 due to orders pushed from Q4 [71][74] Question: What are the margin assumptions for 2024? - Management confirmed that there will be some margin pressure due to ongoing recovery from the cybersecurity incident, but improvements in margins are expected as revenues ramp up throughout the year [83] Question: How does the company plan to close the gap in merchandise sales related to the cybersecurity incident? - Management noted that the incident affected impulse shoppers and pricing visibility, but they are confident in their e-commerce recovery efforts and expect to regain business over the next few months [122][126]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Commission file number 0-27078 HENRY SCHEIN, INC. (Exact name of registrant as specified in its charter) Delaware 11-3136595 incorporation or organization) (State or other jurisdiction of (I.R.S. Employer Identification No.) 135 Duryea Road Melville, New York (Address of principal executive offices) 11747 (Zip Code) (631) 843-5500 (Registrant's telephone number, including area code) Securities registered pursuant to ...

For the quarter ended December 2023, Henry Schein (HSIC) reported revenue of $3.02 billion, down 10.5% over the same period last year. EPS came in at $0.66, compared to $1.21 in the year-ago quarter.The reported revenue represents a surprise of -1.83% over the Zacks Consensus Estimate of $3.07 billion. With the consensus EPS estimate being $0.70, the EPS surprise was -5.71%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...